Recent Articles in IPO/Stock Watch

Shanghai AoHua Endoscope completed a $117 million IPO on the Shanghai Star Exchange and rose 71% higher in its first trading session, bringing its market capitalization to over $800 million. Formed in 1994, AoHua develops and sells electronic endoscopic equipment and surgical consumables, making products for  gastroenterology, respiratory medicine, otolaryngology, gynecology, and emergency medicine uses. The company's stated goal is to become the world's leading provider of endoscope technology. More details....

Stock Symbol: (SHA: 688212)

Share this with colleagues:

LianBio, a Princeton-Shanghai company, raised $325 million in its NASDAQ IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. LianBio was formed by Perceptive Advisors as a way for the US company to participate in China's market. It has access to the China rights for Perceptive's portfolio of life science companies, though it doesn't have a lock on those rights. Perceptive seeded the company originally, which then raised $310 million from outside investors soon after breaking out of stealth mode one year ago. More details....

Stock Symbol: (NSDQ: LIAN)

Share this with colleagues:

Hangzhou Microtech Medical staged a $233 million IPO on the Hong Kong Exchange to support its portfolio of diabetes care products. The company has developed products that include a closed loop artificial pancreas, a second-gen patch insulin pump system, continuous glyclose monitoring and IVD devices. With its R&D, manufacturing and commercialization capabilities, Microtech aims to provide a whole-process platform of diabetes products that address monitoring, treatment and chronic disease management. The IPO priced the company at a market capitalization of $1.7 billion. More details....

Stock Symbol: (HK: 2236)

Share this with colleagues:

Abbisko, a Shanghai biopharma, completed a $226 million IPO in Hong Kong to support its small molecule therapies for cancer. At the IPO price, Abbisko has a $1.1 billion market capitalization. Formed in 2016, Abbisko has developed a portfolio of 14 drug candidates, five of them at clinical stage. Its lead program, a pan-FGFR inhibitor aimed at urothelial carcinoma, is partnered with AstraZeneca. The company plans to start Phase Ib/II China trials for the candidate soon. More details....

Stock Symbol: (HK: 2256)

Share this with colleagues: